Oncology Technology Articles & Analysis
31 news found
Saudi Arabia is undergoing rapid healthcare transformation under Vision 2030, with significant investments in oncology infrastructure and advanced radiotherapy technologies. With this authorization in place, RTsafe is positioned to collaborate with leading cancer centers and healthcare providers across the Kingdom, supporting national initiatives focused on ...
ByRTsafe
Medical science is witnessing remarkable advancements in neurology and oncology, with cutting-edge technologies shaping the future of patient care. Transcranial techniques are improving neurological diagnostics, while tumor tissue-based technology is revolutionizing cancer treatment, particularly in prostate cancer screening. ...
To facilitate these services, the company has established one of the largest and most comprehensive databases of metabolic health profiles across healthy and diseased individuals covering multiple age and gender groups as well as specific diseases in neurology, oncology, and inflammation. Lifespin, a deep data company that maps human health based on snapshots of metabolic ...
Inspirata Inc. and FUJIFILM Corporation signed an asset purchase agreement for Fujifilm to acquire Inspirata’s Dynamyx® digital pathology technology, employees and customers, building off the proven success of the established partnership between the companies in UK and Europe. ...
In America, much attention is paid to medical equipment. Local oncology centers are equipped with the latest technology, actively use innovative technologies and new medicines. In addition, oncology in the United States involves extensive screening and more aggressive anticancer treatment. ...
The study was conducted as a collaboration between Atrium Health Levine Cancer Institute, Sanofi, and GeneCentric and evaluated real-world data from patients diagnosed with renal cell carcinoma (RCC) who were treated with immune-oncology agents. Results suggest that common and distinct immune-related response markers for IL-2 and anti-PD-(L)1 therapy may help guide their use, ...
EsoCap AG organized a multidisciplinary scientific advisory board meeting with eight international experts in Barrett’s esophagus (BE) in Zurich EsoCap’s technology for the topical treatment of Barrett’s esophagus was recognized by the experts for having high potential for clinical success EsoCap’s proprietary and unique targeted application ...
Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with solid and hematologic malignancies, and TreeFrog Therapeutics, a biotechnology company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), announced today that ...
In addition, the company is collaborating with Spark Therapeutics (a member of the Roche Group) and BlueRock Therapeutics (a wholly-owned and independently operated subsidiary of Bayer AG) on applications of its gene circuit technology outside of oncology. Omid Farokhzad, MD, Executive Chair of the DYNS Board of Directors, said, “We believe in the powerful ...
” “The mission of Advanced BioMatrix is to enable the future of life-saving treatments, and the HyStem technology can now be more fully utilized as a tool towards accomplishing this mission,” added Bowman Bagley, Advanced BioMatrix CEO. ...
Zuiverloon, MD, Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands Abstract Number: 22-2937 Session: MP59: Bladder Cancer: Non-Invasive III Date: Monday, May 16, 2022 Time: 1:00-2:15 PM CDT About GeneCentric GeneCentric Therapeutics, Inc. is an RNA-based genomic solutions provider based in Durham, North Carolina. The company designed its ...
“The acquisition of ModeX Therapeutics significantly broadens our technology foundation and expands our product pipeline to include multi-specific multi-functional antibodies focused on a range of cancers and infectious diseases, with applicability to other therapeutic areas. ...
Lineage’s clinical programs are in markets with billion dollar opportunities and include five allogeneic (“off-the-shelf”) product candidates: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 1/2a development for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a ...
“It is natural that, on the heels of the announcement of our alliance with Roche and Genentech for our RPE cell therapy, a deal worth up to $670 million dollars plus double-digit royalties if certain development, approval, and sales milestones are achieved and other conditions are met, that we also would pursue treatments for vision loss through the other major cell type of the retina, the ...
Graduate from the Ecole Polytechnique engineering school in Paris, France, Elsy Boglioli holds a master’s degree in Economy and Management from the Pompeu Fabra University, Barcelona, Spain, and was trained in immuno-oncology at the Gustave Roussy Institute of Oncology, Paris, France. ...
VAC2, which is produced from a pluripotent cell technology using a directed differentiation method, is comprised of a population of nonproliferating mature dendritic cells. ...
Incorporated in Bordeaux, France, in 2018, TreeFrog Therapeutics introduces a breakthrough technology for the development and bioproduction of iPSC-derived cell therapies: C-StemTM. ...
In addition to the speed with which the team created this new program from our internal technology, we have done so with a modest investment of capital so far, because we were able to take advantage of our established manufacturing infrastructure and broad knowhow in the expansion and differentiation of pluripotent cells. This is another example of the efficiency and versatility ...
Title: Prognostic and predictive applications from mesenchymal gene expression subtype analysis for early-stage, HPV(-) head and neck squamous cell carcinoma First Author: Neil Hayes, MD, MPH, Department of Medical Oncology, University of Tennessee Health Science Center’s Center for Cancer Research, Memphis, Tennessee Abstract Number: 2142 Session: Session MS.CL11.02 ...
Feeney’s expertise building sales and market access teams across specialty areas, including liquid biopsy, oncology, and women's health, will play a critical role in advancing the commercial strategy and development of 4D Path’s cancer diagnostic and precision oncology platform technology. ...